CRBN/DDB1 complex protein: Structural basis of the substrate recognition module of the E3 ubiquitin ligase and a drug development platform

Author: Senior Product Manager of UA Views：10

This article systematically elaborates on the molecular characteristics and biological functions of the CRBN/DDB1 complex protein, describing the structural localization of CRBN as the substrate recognition component of the CUL4-RBX1-DDB1-CRBN E3 ubiquitin ligase complex and its interaction mode with the DDB1 adaptor protein, analyzing the molecular mechanism by which the CRBN C-terminal aromatic cage forms the immunomodulatory drug binding pocket and mediates the recruitment of endogenous and neo-substrates, and discussing the core platform value of this complex in the design of PROTACs and molecular glue degraders as well as the advantages of CRBN-based degraders in the chemical space of oral absorption.

Recent Advances
Product Information

Recent Advances

CRBN/DDB1 Complex Protein: Structural Basis of the Substrate Recognition Module of the E3 Ubiquitin Ligase and a Drug Development Platform

Brief introduction: This article focuses on the molecular characteristics and biological functions of the CRBN/DDB1 complex protein. It systematically describes the structural localization of CRBN as the substrate recognition component of the CUL4-RBX1-DDB1-CRBN E3 ubiquitin ligase complex and its interaction mode with the DDB1 adaptor protein, analyzes the molecular mechanism by which the CRBN C-terminal aromatic cage forms the immunomodulatory drug binding pocket and mediates the recruitment of endogenous and neosubstrates, and discusses the core platform value of this complex in the design of PROTACs and molecular glue degraders as well as the advantages of CRBN-based degraders in the chemical space for oral absorption.

I. The rise of CRBN ligands and the landscape of the targeted protein degradation field.

In recent years, CRBN ligands have gradually become a very popular class of E3 ligase ligands. They can be used not only as E3 ligase ligands for designing and synthesizing PROTACs but also for designing molecular glue degraders, playing a very important role in the PROTAC and molecular glue fields. The most commonly used E3 ligases for PROTACs are VHL and CRBN, and CRBN-based PROTACs occupy a more suitable chemical space for oral absorption relative to VHL-based PROTACs. Multiple CRBN-based PROTACs have entered clinical studies, including the two most famous compounds ARV-110 and ARV-471, among which ARV-471 has entered phase III clinical trials. At present, the CRBN ligands mainly used for PROTACs and molecular glues are still immunomodulatory inhibitors. The formation of this landscape stems both from the smaller molecular weight and better physicochemical properties of CRBN ligands and from the drug development convenience brought by the broad expression of CRBN in human tissues.

II. The overall architecture of the CRL4-CRBN complex and the substrate recognition localization of CRBN.

PROTAC is an emerging field that has been intensely researched in recent years. CRBN-based PROTACs recruit the CRBN complex close to the target protein, causing the target protein to undergo polyubiquitination and thereby be degraded by the proteasome. CRBN is the substrate recognition component of the CUL4-RBX1-DDB1-CRBN E3 ubiquitin ligase complex, while DDB1 acts as an adaptor protein that connects CRBN to the core CUL4-RBX1 catalytic unit. The CRBN gene is located on human chromosome 3q26.2, encodes a protein of approximately 50 kDa, and is widely expressed in the central nervous system, kidneys, liver, and retina. This three-tier architecture of “catalytic core—adaptor—substrate receptor” determines that the CRBN complex can both maintain the catalytic efficiency of the ubiquitin transfer reaction and achieve selective recognition of different target proteins by exchanging the substrate receptor, which is the structural prerequisite for the modular design of PROTAC technology.

III. The interaction mode between CRBN and DDB1 and complex assembly.

In the CRL4-CRBN complex, DDB1 connects the ligase core to the substrate receptor. CRBN interacts with the BPC domain of DDB1 through its C-terminal domain and is anchored to the ligase. This interaction is the physical basis for CRBN to perform its function—CRBN itself does not possess catalytic activity; only by binding to DDB1 and being anchored onto the CUL4-RBX1 catalytic core can it deliver the substrates it recognizes to the center of the ubiquitin transfer reaction. Therefore, the assembly of the CRBN-DDB1 complex is not simple co-localization but a key structural event that determines the functional activity of the entire E3 ligase. Understanding this assembly mechanism is of great significance for reconstructing functional CRBN complexes in vitro and for evaluating the ternary complex formation ability of PROTAC molecules.

IV. The CRBN C-terminal aromatic cage and the immunomodulatory drug binding pocket.

The C-terminal region of CRBN forms an aromatic cage composed of three tryptophan residues, Trp380, Trp386, and Trp400, constituting the binding pocket for immunomodulatory drugs. This aromatic cage is the structural basis for CRBN to recognize thalidomide and its derivatives—immunomodulatory drugs achieve high-affinity binding to CRBN through hydrophobic stacking and hydrogen bond networks formed between their glutarimide ring and the tryptophan residues within the aromatic cage. The presence of the aromatic cage makes CRBN a substrate receptor that can be “programmed by small molecules”: small molecule binding does not block CRBN function but instead remodels its substrate recognition interface, and this property is precisely the fundamental difference between CRBN and traditional drug targets.

V. The dual functional mode of endogenous substrate and neosubstrate recruitment.

In the basal state, CRBN recognizes and mediates the ubiquitination and degradation of endogenous substrates such as the transcription factor MEIS2. When its analogs bind, CRBN forms a neosubstrate interaction interface, thereby recruiting and degrading neosubstrates such as the transcription factors IKZF1/IKZF3 and the kinase CK1α, which are not normally recognized. This dual functional mode of “maintaining normal turnover of basal substrates and recruiting neosubstrates upon ligand binding” is the core of the mechanism of action of molecular glue degraders—molecular glues do not simply block CRBN function but create new protein-protein interaction interfaces by altering the surface conformation of CRBN, bringing proteins originally not recognized by CRBN into the degradation scope. This mechanism also explains why CRBN ligands can be used both for molecular glue design and as the E3 recruitment end of PROTACs.

VI. Conclusion.

In basic research related to the CRBN/DDB1 complex and in targeted protein degradation drug development, high-quality recombinant complex proteins are core tools for dissecting its assembly mechanism, evaluating ligand binding activity, and conducting ternary complex formation analysis. The GST tag facilitates efficient purification by glutathione affinity chromatography and can serve as a detection tag for analyses such as enzyme-linked immunosorbent assay and surface plasmon resonance. In response to the needs of CRBN/DDB1 complex functional research and PROTAC and molecular glue drug development, Ulab provides CRBN/DDB1 Complex GST Tag Protein, Human. This product is suitable for applications such as studies of CRBN-DDB1 interaction and complex assembly mechanisms, binding activity evaluation and screening of immunomodulatory drugs and CRBN ligands, analysis of ternary complex formation induced by PROTAC molecules, and exploration of molecular glue-mediated neosubstrate recruitment mechanisms.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next